8-K current report · filed Sep 8, 2026

BridgeBio Oncology Therapeutics Inc (BBOT) 8-K Current Report: September 8, 2026

Item 8.01Item EX-99.1Item EX-99.2BBOT overview

Short answer

BridgeBio Oncology Therapeutics Inc (BBOT) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). September 8, 2026 press release highlights new BBO-8520 data and strategic focus on 2L+ NSCLC combinations.

BridgeBio Oncology Therapeutics Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • September 8, 2026 press release highlights new BBO-8520 data and strategic focus on 2L+ NSCLC combinations
  • Pipeline emphasis includes BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers
  • Updated corporate presentation reflects recent corporate developments and provides additional investor context

Item EX-99.1 · Exhibit EX-99.1

  • BBO-8520 plus pembrolizumab produced 75% ORR at 500 mg QD in 2L+ NSCLC after prior KRAS G12C inhibitor treatment
  • BBO-8520 monotherapy delivered 63% ORR and 100% DCR in 41 previously untreated 2L+ NSCLC patients
  • No grade 3 liver enzyme elevations reported for BBO-8520 monotherapy, supporting continued combination development
  • BBOT prioritizing BBO-8520 combination and BBO-11818/BBO-10203 combinations across KRAS-mutant cancers
  • $344.1M liquidity as of June 30, 2026, projected to fund operations into 2028; key data readouts extend through mid-2027

Item EX-99.2 · Exhibit EX-99.2

  • BBOT prioritizing BBO-8520 plus pembrolizumab in post-G12C NSCLC, while deprioritizing 1L NSCLC development and further BBO-8520 investment there
  • BBO-8520 combination delivered 75% ORR at 500 mg QD and 53% across doses in 17 G12C inhibitor experienced patients
  • BBO-11818 and BBO-10203 advancing in KRAS-mutant cancers, with CRC and PDAC combination cohorts enrolling
  • BBO-11818 and BBO-10203 data catalysts planned for Q4 2026, increasing near-term clinical readout significance
  • $344M cash at Q2 2026 supports projected operations into 2028, reducing near-term financing risk

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other BridgeBio Oncology Therapeutics Inc 8-K filings

Get the next BBOT 8-K as it lands

Follow BBOT for push alerts, or ask the research agent what this filing means.